Article
ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
Annals of hematology - 1 Feb 2022
Keren-Froim Naama, Heering Gabriel, Sharvit Gal, Zlotnik Maya, Nagler Arnon, Shimoni Avichai, Avigdor Abraham, Canaani Jonathan
Abstract excerpt
Early mortality remains a challenging therapeutic facet of the initial induction phase of intensive chemotherapy in patients with acute myeloid leukemia (AML). The impact of standard molecular evaluation and risk category of the European LeukemiaNet (ELN) 2017 classification model on early mortality has not been rigorously evaluated thus far. We reviewed the medical records of 320 consecutive adult patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
